Robert J. More

Robert J. More joined Frazier Healthcare Ventures in 2008 as a General Partner and is a member of the firm’s biopharmaceutical and medical device investment teams. Prior to joining Frazier Healthcare, Mr. More was a Partner with Domain Associates, LLC, having joined the firm in 1996 as a Kauffman Fellow and becoming a Partner in 2000. From 1997 to 1998, Mr. More served as the COO of Small Molecule Therapeutics, Inc., a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Mr. More was a sales professional at Pharmacia Biotech. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, Inc., a company developing a recombinant blood substitute that was subsequently bought by Baxter Healthcare. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, DC. Mr. More has managed successful investments in and served on the boards of ESP Pharma Inc. (acquired by Protein Design Labs, Inc.), Proxima Therapeutics, Inc. (acquired by Cytyc Corporation), Onux Medical, Inc. (acquired by C.R. Bard, Inc.), NovaCardia, Inc. (acquired by Merck & Co., Inc.), Esprit Pharma, Inc. (acquired by Allergan, Inc.) and IntraLase Corporation (acquired by Advanced Medical Optics, Inc.). He serves as an advisory board member for Montagu Newhall Associates, Okapi Venture Capital, the Medical Industry Group of the National Venture Capital Association, and the Sulpizio Family Cardiovascular Center. He is also a past founding board member of the Kauffman Fellows Program. Mr. More received his MBA from the Darden School of Business Administration at the University of Virginia and a BA from Middlebury College.